Retension Pharmaceuticals announces pricing of initial public offering
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
01:58:42 AM UTC
SquawkNews
Retension Pharmaceuticals Announces Pricing of Upsized Initial Public Offering >RTSN
01:58:43 AM UTC
SquawkNews
Retension Pharmaceuticals Plans to Use Net Proceeds From the Offering to Help Complete Phase 2b Clinical Trial of RTN-001 in Uncontrolled Hypertension >RTSN
01:58:46 AM UTC
SquawkNews
Retension Pharmaceuticals Expects Gross Proceeds of $45M From the Offering >RTSN
02:00:06 AM UTC
SquawkNews
(MORE TO FOLLOW) Dow Jones Newswires October 08, 2026 21:58 ET (01:58 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.